| Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages A Obradovic, N Chowdhury, SM Haake, C Ager, V Wang, L Vlahos, ... Cell 184 (11), 2988-3005. e16, 2021 | 230 | 2021 |
| Biomarkers for immunotherapy in bladder cancer: a moving target DH Aggen, CG Drake Journal for immunotherapy of cancer 5, 1-13, 2017 | 181 | 2017 |
| Bismuth compounds in organic synthesis. Bismuth nitrate catalyzed chemoselective synthesis of acylals from aromatic aldehydes DH Aggen, JN Arnold, PD Hayes, NJ Smoter, RS Mohan Tetrahedron 60 (16), 3675-3679, 2004 | 139 | 2004 |
| A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs) JD Stone, DH Aggen, A Schietinger, H Schreiber, DM Kranz Oncoimmunology 1 (6), 863-873, 2012 | 132 | 2012 |
| Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates CH Lee, MH Voss, MI Carlo, YB Chen, M Zucker, A Knezevic, ... Journal of Clinical Oncology 40 (21), 2333-2341, 2022 | 126 | 2022 |
| Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses DH Aggen, CR Ager, AZ Obradovic, N Chowdhury, A Ghasemzadeh, ... Clinical Cancer Research 27 (2), 608-621, 2021 | 100 | 2021 |
| Engineering higher affinity T cell receptors using a T cell display system AS Chervin, DH Aggen, JM Raseman, DM Kranz Journal of immunological methods 339 (2), 175-184, 2008 | 100 | 2008 |
| Considerations for treatment duration in responders to immune checkpoint inhibitors TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ... Journal for immunotherapy of cancer 9 (3), 2021 | 94 | 2021 |
| Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain VαVβ fragments SA Richman, DH Aggen, ML Dossett, DL Donermeyer, PM Allen, ... Molecular immunology 46 (5), 902-916, 2009 | 85 | 2009 |
| Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains DH Aggen, AS Chervin, TM Schmitt, B Engels, JD Stone, SA Richman, ... Gene therapy 19 (4), 365-374, 2012 | 80 | 2012 |
| Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection TM Schmitt, DH Aggen, IM Stromnes, ML Dossett, SA Richman, DM Kranz, ... Blood, The Journal of the American Society of Hematology 122 (3), 348-356, 2013 | 76 | 2013 |
| Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial SA Funt, M Lattanzi, K Whiting, H Al-Ahmadie, C Quinlan, MY Teo, ... Journal of Clinical Oncology 40 (12), 1312-1322, 2022 | 69 | 2022 |
| Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors DH Aggen, AS Chervin, FK Insaidoo, KH Piepenbrink, BM Baker, ... Protein Engineering, Design & Selection 24 (4), 361-372, 2011 | 63 | 2011 |
| Human single-chain T cell receptors DM Kranz, DH Aggen US Patent 10,464,987, 2019 | 52 | 2019 |
| T cell receptor engineering JD Stone, AS Chervin, DH Aggen, DM Kranz Methods in enzymology 503, 189-222, 2012 | 52 | 2012 |
| A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control JD Stone, DT Harris, CM Soto, AS Chervin, DH Aggen, EJ Roy, DM Kranz Cancer immunology, immunotherapy 63, 1163-1176, 2014 | 46 | 2014 |
| Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro TM Schmitt, DH Aggen, K Ishida-Tsubota, S Ochsenreither, DM Kranz, ... Nature biotechnology 35 (12), 1188-1195, 2017 | 43 | 2017 |
| Targeting PD-1 or PD-L1 in metastatic kidney cancer: combination therapy in the first-line setting DH Aggen, CG Drake, BI Rini Clinical Cancer Research 26 (9), 2087-2095, 2020 | 42 | 2020 |
| Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: results of a phase 2 trial. CH Lee, MH Voss, MI Carlo, YB Chen, E Reznik, A Knezevic, ... Journal of Clinical Oncology 39 (15_suppl), 4509-4509, 2021 | 36 | 2021 |
| Opposite effects of endogenous peptide–MHC class I on T cell activity in the presence and absence of CD8 JD Stone, DH Aggen, AS Chervin, S Narayanan, TM Schmitt, ... The Journal of Immunology 186 (9), 5193-5200, 2011 | 23 | 2011 |
David Kranz在 illinois.edu 的电子邮件经过验证
